Cargando...
Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy
Ospemifene—a third-generation selective estrogen receptor modulator approved by the Food and Drug Administration in 2013—is an oral medication for the treatment of dyspareunia. In postmenopausal women with vulvovaginal atrophy, ospemifene significantly improves the structure and pH levels of the vag...
Guardado en:
| Publicado en: | J Menopausal Med |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
The Korean Society of Menopause
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5606913/ https://ncbi.nlm.nih.gov/pubmed/28951854 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6118/jmm.2017.23.2.79 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|